Generic schizophrenia drug shows promise in early test

NCT ID NCT07266792

Completed Knowledge-focused Sponsor: Humanis Saglık Anonim Sirketi Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a generic version of the schizophrenia drug brexpiprazole works the same as the brand-name drug (Rxulti). Thirty-six healthy adults took a single dose of each version, and researchers measured drug levels in their blood. The goal was to see if the generic is absorbed similarly, which could lead to a more affordable treatment option.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Brexpiprazole
What this could lead to: If successful, this could show that the generic version of brexpiprazole is equivalent to the brand-name drug, potentially offering a lower-cost option for schizophrenia treatment.
What could go wrong: This was a small, early-phase study in healthy people, not patients. It only measured drug levels in the blood, not actual treatment effects or safety in schizophrenia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA

Contacts and locations

Locations

Cliantha Research Limited

Ahmedabad, Gujarat, 382210, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.